Literature DB >> 34161992

Hepatic Alveolar Echinococcosis.

Solange Bresson-Hadni1,2,3, Laurent Spahr1, François Chappuis2.   

Abstract

Hepatic alveolar echinococcosis (HAE) is a rare but severe zoonosis caused by the pseudotumoral intrahepatic development of the larval stage of the tapeworm Echinococcus multilocularis. HAE is present only in the Northern Hemisphere, predominantly in China. Currently, there is a significant resurgence of cases in historically endemic areas associated with emergence of HAE in countries not previously concerned. Today, in European countries, HAE is often discovered by chance; however, clinicians should be made aware of opportunistic infections that progressively emerged recently as a result of therapeutic or pathological immunosuppression. Ultrasonography is the key first-line diagnostic procedure, with specific serology providing confirmation in 95% of the cases. Albendazole, only parasitostatic, is the mainstay for treatment. Surgical resection, if feasible, is the gold standard for treatment, and more patients are currently eligible for this option because of an earlier diagnosis. The prognosis has considerably improved but remains poor in countries where access to care is less favorable. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 34161992     DOI: 10.1055/s-0041-1730925

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  8 in total

1.  Analysis of Ultrasonographic Characteristics of Early Hepatic Alveolar Echinococcosis.

Authors:  Yong-Xing Wang; Wei Liu; Zhan-Yong Sun; Lan Wu; Xian-Kun Xie; Bo Liu
Journal:  Front Surg       Date:  2022-07-05

2.  Is long-term follow-up without surgical treatment a valid option for hepatic alveolar echinococcosis?

Authors:  Yusufukadier Maimaitinijiati; Yuan Meng; Xiong Chen
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

3.  Characteristics and Clinical Course of Alveolar Echinococcosis in Patients with Immunosuppression-Associated Conditions: A Retrospective Cohort Study.

Authors:  Ansgar Deibel; Cordula Meyer Zu Schwabedissen; Lars Husmann; Felix Grimm; Peter Deplazes; Cäcilia S Reiner; Beat Müllhaupt
Journal:  Pathogens       Date:  2022-04-06

4.  Evaluation of Serological Markers in Alveolar Echinococcosis Emphasizing the Correlation of PET-CTI Tracer Uptake with RecEm18 and Echinococcus-Specific IgG.

Authors:  Julian Frederic Hotz; Lynn Peters; Silke Kapp-Schwörer; Frauke Theis; Nina Eberhardt; Andreas Essig; Beate Grüner; Jürgen Benjamin Hagemann
Journal:  Pathogens       Date:  2022-02-12

5.  Imaging Aspects of Hepatic Alveolar Echinococcosis: Retrospective Findings of a Surgical Center in Turkey.

Authors:  Mecit Kantarci; Sonay Aydin; Suat Eren; Hayri Ogul; Okan Akhan
Journal:  Pathogens       Date:  2022-02-20

Review 6.  Role of the radiologist in the diagnosis and management of the two forms of hepatic echinococcosis.

Authors:  Paul Calame; Mathieu Weck; Andreas Busse-Cote; Eleonore Brumpt; Carine Richou; Celia Turco; Alexandre Doussot; Solange Bresson-Hadni; Eric Delabrousse
Journal:  Insights Imaging       Date:  2022-04-08

7.  Alveolar Echinococcosis-A Challenging Task for the Hepatobiliary Surgeon.

Authors:  Jens Strohaeker; Mihaly Sulyok; Alfred Koenigsrainer; Silvio Nadalin
Journal:  Pathogens       Date:  2021-12-31

8.  Echinococcus multilocularis drives the polarization of macrophages by regulating the RhoA-MAPK signaling pathway and thus affects liver fibrosis.

Authors:  Shigui Chong; Gen Chen; Zhisheng Dang; Fuqiu Niu; Linghui Zhang; Hui Ma; Yumin Zhao
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.